Nakashima Megan O, Durkin Lisa, Bodo Juraj, Lin Jeffrey, Quintanilla-Martinez Leticia, Fu Kai, Hsi Eric D
*Department of Clinical Pathology, Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH †Institute of Pathology, Eberhard-Karls-University of Tübingen, Tübingen, Germany ‡Department of Pathology and Microbiology, University of Nebraska Medical, Center, Omaha, NE.
Appl Immunohistochem Mol Morphol. 2014 Nov-Dec;22(10):720-7. doi: 10.1097/PAI.0000000000000067.
Mantle cell lymphoma (MCL) is classically characterized by t(11;14) leading to cyclin D1 overexpression. Recently the transcription factor SOX11 has been discovered to be expressed in most MCL, including cyclin D1-negative cases. In this study we assess the performance of 2 commercially available monoclonal antibodies, Atlas Antibodies (Stockholm, Sweden) clone CLO142 and Cell Marque (Rocklin, CA) clone MRQ-58, for SOX11 immunohistochemistry in MCL, both cyclin D1 positive and cyclin D1 negative, as well as in cases of other small B-cell lymphoproliferative disorders, diffuse large B-cell lymphomas (DLBCLs), Burkitt lymphomas, and lymphoblastic leukemia/lymphomas. We also performed Western blots to further characterize the antibody specificity. Both antibodies show reliable, clear nuclear staining in MCL with variable specificity. However, the MRQ-58 antibody was more specific for MCL than CLO142, which showed considerably more nonspecific staining, especially in DLBCLs (59% positive vs. 4% positive with MRQ-58). In addition we reconfirmed the utility of SOX11 IHC for identifying cases of cyclin D1-negative blastoid MCL. However, we also identified cases of SOX11-positive DLBCL and splenic marginal zone lymphoma. Although SOX11 IHC is a powerful, and relatively accessible, tool to identify MCLs with variant immunophenotypes and/or morphology, these latter 2 cases highlight the need for strict criteria for interpreting SOX11 staining.
套细胞淋巴瘤（MCL）的典型特征是t(11;14)，导致细胞周期蛋白D1过表达。最近发现转录因子SOX11在大多数MCL中表达，包括细胞周期蛋白D1阴性的病例。在本研究中，我们评估了两种市售单克隆抗体，即阿特拉斯抗体公司（瑞典斯德哥尔摩）的克隆CLO142和细胞标志物公司（加利福尼亚州罗克林）的克隆MRQ-58，用于MCL（细胞周期蛋白D1阳性和阴性）以及其他小B细胞淋巴增殖性疾病、弥漫性大B细胞淋巴瘤（DLBCL）、伯基特淋巴瘤和淋巴细胞白血病/淋巴瘤病例中SOX11免疫组织化学的性能。我们还进行了蛋白质印迹分析以进一步表征抗体特异性。两种抗体在MCL中均显示出可靠、清晰的核染色，但特异性有所不同。然而，MRQ-58抗体对MCL的特异性高于CLO142，CLO142显示出更多的非特异性染色，尤其是在DLBCL中（59%阳性，而MRQ-58为4%阳性）。此外，我们再次证实了SOX11免疫组织化学在识别细胞周期蛋白D1阴性母细胞样MCL病例中的实用性。然而，我们也发现了SOX11阳性的DLBCL和脾边缘区淋巴瘤病例。尽管SOX11免疫组织化学是识别具有变异免疫表型和/或形态的MCL的一种强大且相对容易获得的工具，但后两种情况凸显了严格解释SOX11染色标准的必要性。
